Pediatr. praxi. 2020;21(3):180-185 | DOI: 10.36290/ped.2020.037

Atopic dermatitis, part II - course of disease, therapy

doc. MUDr. Jarmila Čelakovská, Ph.D.
Klinika nemocí kožních a pohlavních, FN Hradec Králové

Atopic dermatitis together with bronchial asthma and allergic rhinitis belong to the so-called atopic diseases. Atopic dermatitis is a chronic, itchy, inflammatory skin disease. Genetic predisposition, abnormal immune response and skin barrier defect are implicated in the etiopathogenesis of this disease. The course of the disease is influenced by environmental factors (food and inhalation allergens, infectious agents, mechanical and chemical stimuli), internal influences (hormonal influences, stress). Interest in this disease is steadily increasing, due to its increasing prevalence and adversely affecting the quality of life. The article summarizes current knowledge about atopic dermatitis. It gives an overview of the clinical manifestations of atopic dermatitis, the severity of the disease, and treatment with both local and systemic medication.

Keywords: atopic dermatitis, severity of atopic dermatitis, local and systemic therapy.

Published: June 3, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čelakovská J. Atopic dermatitis, part II - course of disease, therapy. Pediatr. praxi. 2020;21(3):180-185. doi: 10.36290/ped.2020.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease‑modifying strategy. Allergy 2012; 40: 969-975. Go to original source...
    2. Bieber T, Leung D. In: Atopic dermatitis. Marcel Dekker, New York, 2002, 365. Go to original source...
    3. Wuthrich B, Schmid‑Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE‑associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. J Investig Allergol Clin Immuno1 2003; 3: 1-5. Go to original source...
    4. Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-1060. Go to original source...
    5. Litvik R. Nové možnosti léčby atopické dermatitidy. Remedia 2018; 6(28): 596-598.
    6. Gelmetti C, Colonna C. The value of scorad and beyond. Towards a standardized evaluation of severity? Allergy 2004; 59 (Suppl. 78): 61-65. Go to original source... Go to PubMed...
    7. Steven R. Feldman MD, et al. The Challenge of Managing Atopic Dermatitis in the United States. Am Health Drug Benefits. 2019 Apr; 12(2): 83-93.
    8. Rademaker M, Agnew K, Andrews M, Baker C, Foley P, Gebauer K, Gupta M, Rubel D, Somerville C, Sullivan J, Wong L. Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative. Australas J Dermatol. 2019 Sep 16. doi: 10.1111/ajd.13141. Go to original source...
    9. Saini S, Pansare M. New Insights and Treatments in Atopic Dermatitis. Pediatr Clin North Am 2019; 66(5): 1021-1033. Go to original source... Go to PubMed...
    10. Chromej, I. Bratislava: Dali Banská Bystrica, 2007: 240 s.
    11. Hong C, Gooderman M, Bissonnette R. Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis. J Cutan Med Surg 2019; 5S-10S. doi: 10.1177/1203475419857669 Go to original source...
    12. Giavina‑Bianchi M, Giavina‑Bianchi P. Systemic Treatment for Severe Atopic Dermatitis. Arch Immunol Ther Exp (Warsz) 2019; 67(2): 69-78. Go to original source...
    13. Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatments with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-1181. Go to original source... Go to PubMed...
    14. Mccollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol 2010; 27: 425-436). Go to original source... Go to PubMed...
    15. Draelos Z, Nayak A, Pariser D, ET AL. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator‑blind comparison. J Am Acad Dermatol 2005; 53: 602-609. Go to original source...
    16. Bieber T, Cork M, Ellis C, Girolomoni G, Groves R, Langley R, Luger T, Meuer M, Murrell D, Orlow S, Paller A, De Pprosty, Puig L, Ring J, Saurat JH, Schwartz T, Shear N, Stingl G, Taieb A, Thestrup‑Pedersen K. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211: 77-78. Go to original source... Go to PubMed...
    17. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011; 165: 465-473. Go to original source... Go to PubMed...
    18. Mahdy AM, Webster NR. Histamine and antihistamines. Anaesth Intensive Care Med 2014; 15: 5. Go to original source...
    19. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128: 1139-1150. Go to original source... Go to PubMed...
    20. Murphy LA, Atherton DJ. Azathioprin as a treatment for severe atopic eczema in children with partial thiopurine methyltransferase deficiency. Pediatr Dermatol 2003; 20: 531-534. Go to original source... Go to PubMed...
    21. Klemens CM, Bermand DR, Mozurkewich EL. The effect of perinatal omega-3 fatty acid supplementation on inflammatory markers and allergic diseases: a systematic review. BJOG 2011; 118: 916-925. Go to original source...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.